NIH Institutional Biosafety Committee Minutes
Location: Rocky Mountain Laboratories
September 18, 2025
1:00 PM – 3:00 PM
Virtual via Microsoft Teams/In person at Building A Room 322

Members Present:
Quorum Met: Yes

☒	Sue Priola	Chair	☐	Alida Merritt	Local Non-Affiliated
☒	Andrea Marzi	Vice Chair	☐	Alexandra Scranton	Member
☒	Rebecca Anderson	Biosafety Officer	☒	Clayton Winkler	Lab Representative
☒	Paul Beare	Lab Representative	☒	Todd Wohlman	Member
☐	Chris Bosio	Lab Representative	☐	Sonja Best	Ex officio
☐	Megan Brose	Member	☐	Marshall Bloom	Ex officio
☐	Larry Brouwer	Local Non-Affiliated	☐	Marcie Caldwell	Ex officio
☐	Chad Clancy	Animal Expert	☐	Frank DeLeo	Ex officio
☐	Erik Hoover	Local Non-Affiliated	☐	Heinz Feldmann	Ex officio
☒	Scott Kobayashi	Lab Representative	☐	Josh Kellar	Ex officio
☒	Jamie Lovaglio	Animal Expert	☐	Brian Vickrey	Ex officio

Guests Present:

Kaitlyn Conners, Shanda Sarchette, Richard Baumann, Grace Markley, Michael Kujawa, Jocelyn Mendoza, Jessica McCormick-Ell

Announcements & Call to Order

I. Meeting called to order by Sue Priola at 1:10 pm.
II. The IBC Chair reminded all members present to identify any conflicts of interest as each registration is reviewed.

Review of Past IBC Meeting Minutes

I. August 21, 2025 Minutes
    a. Comments on minutes
        i. Clarify that the PI needs to spell out oral or esophogeal route of inoculation for Feldmann 24-RML-003 Amend and Feldmann PRD-23-202 Amend
        ii. Correct the numbering in the section for Long RD-23-500.
        iii. There were a few minor typos to correct.
    b. The minutes were unanimously approved with minor modifications

New Committee Business

I. BSO or IBC lead reviewer preliminary registration approvals since the previous meeting
    a. Pathogen only Registration Numbers – None
    b. rDNA and rDNA/pathogen Registration Numbers: None

c. Registration amendments summary: None
d. Committee Discussion: None

II. Registrations for Committee review

a. Registrations for committee review:
    i. None

b. Registration amendments for committee review:

Sonja Best, PRD-23-255 Amend

i. Reviewers: Not applicable; No recombinant DNA work
ii. Review Summary and risk assessment: The amendment to the registration is to add animal work with mice. The purpose of the proposed experiments is to determine the cell type-specific role of mitochondrial antiviral signaling protein in protection from infection with Venezuelan Equine Encephalitis virus (VEEV) and the vaccine strain TC-83 by using mouse strains that lack mitochondrial antiviral signaling protein (MAVS) only in one cell type. Animals will be inoculated via subcutaneous or intranasal route with one of the Alphaviruses (VEEV or TC-83 strain). Analyses will include survival, clinical symptoms and viral replication. Major hazards would be animal bites and personnel will wear appropriate PPE for animal handling.
iii. Committee Discussion: Fix typo in MAVS, Under Animal-Mice section, "The infectious material I am using will be non-replicative in this study" needs to be changed to unchecked.
iv. Minimum PPE required, special practices, and recommended OMS consult if applicable: Disposable gown, double gloves, N95 or PAPR, shoe covers and hair cover (for animal work if wearing N95).
v. Training:
    1. Laboratory safety training (includes BBP training)
    2. BSL-3 laboratory biosafety training
vi. Animal studies proposed: Yes. Mice.
vii. The committee discussed the dual-use and ePPP potential of these experiments. The committee agreed that there were no dual-use or ePPP concerns with the proposal. The proposed animal work was previously approved by the DURC-IRE.
viii. Work is approved at ABSL-3
ix. Relevant sections of the NIH Guidelines: Not applicable; no recombinant work
x. A motion was made to approve the registration pending the following changes or conditions.
    1. Fix typo with MAVS
    2. Uncheck the infectious material will be non-replicative in the study.
xi. The committee unanimously approved with minor modifications.
    1. Conflicts of Interest: None
    2. Votes for: _8____ Votes against: _0_____Abstained: __0_____

Sonja Best, PRD-24-263 Amend

i. Reviewers: Not applicable; No recombinant DNA work
ii. Review Summary and risk assessment: The amendment to the registration is to add animal work with mice. The purpose of the proposed experiments is to determine the cell type-specific role of mitochondrial antiviral signaling protein in protection from infection with VEEV and the vaccine strain TC-83 by using mouse

strains that lack MAVS only in one cell type. Animals will be inoculated via subcutaneous or intranasal route with one of the Alphaviruses (VEEV or TC-83 strain). Analyses will include survival, clinical symptoms and viral replication. Major hazards would be animal bites and personnel will wear appropriate PPE for animal handling.

iii. Committee Discussion: Fix typo in MAVS, Remove Vaccine strain information since it is not applicable to this registration, Under Animal-Mice section, "The infectious material I am using will be non-replicative in this study" needs to be changed to unchecked, add in "electronic database" for keeping track of select agent materials.

iv. Minimum PPE required, special practices, and recommended OMS consult if applicable: Disposable gown, double gloves, N95 or PAPR, shoe covers and hair cover (for animal work if wearing N95).

v. Training:
   1. Laboratory safety training (includes BBP training)
   2. BSL-3 laboratory biosafety training

vi. Animal studies proposed: Yes. Mice.

vii. The committee discussed the dual-use and ePPP potential of these experiments. The committee agreed that there were no dual-use or ePPP concerns with the proposal. The proposed animal work was previously approved by the DURC-IRE.

viii. Work is approved at ABSL-3

ix. Relevant sections of the NIH Guidelines: Not applicable; no recombinant work

x. A motion was made to approve the registration pending the following changes or conditions.
   1. Fix typo with MAVS
   2. Remove vaccine strain information
   3. Uncheck the infectious material will be non-replicative in the study
   4. Check box for electronic database

xi. The committee unanimously approved with minor modifications.
   1. Conflicts of Interest: None
   2. Votes for: _8____ Votes against: _0_____Abstained: __0_____

III. Committee Review of Inactivation Procedures (if not reviewed under a registration)
   a. None

IV. Standard Operating Procedures/Plans
   a. 25-BSL3 OSP & 25-ABSL3 OSP Updates
      i. SOP Summary: Minor changes for names. Division of Occupational Health and Safety was updated to Division of Safety; Occupational Medical Service updated to Division of Occupational Medical Service; DSAT updated to DRSC, Division of Regulatory Science and Compliance; everything else the same in both OSPs.
      ii. Committee Discussion: Page 3 needs the reasons for revisions section completed. Questions were raised on how to refer to ERS at the beginning or middle of a sentence.
      iii. A motion was made to approve the plans pending the following changes or conditions
         1. Update the Reason for revisions section
         2. Correct usage of ERS at the beginning of a sentence.

iv. The committee unanimously approved with minor modifications.
    1. Conflicts of Interest: None
    2. Votes for: _8____ Votes against: __0____Abstained: __0_____

V. Serious Adverse Events in Clinical Trials reviewed by the Committee
    a. None

Reports

I. Biosafety Officer Report – See attached

Around the Room/Committee Discussion

I. Jessica McCormick-Ell made an announcement on a new initiative that Dr. Bhattacharya & the office of Science Policy where there would be listening sessions from the public concerning reviews of biosafety and NIH guidelines. Dr. McCormick-Ell promoted awareness of the sessions and encouraged people to register for the sessions. Feedback was welcomed on how to change NIH guidelines or things that needed to be added, as well as on how biosafety policy should be. Dr. McCormick-Ell also informed the committee that Dr. Bloom will be providing a short summary about the posting of the IBC minutes to the local community group at RML.

Adjournment

I. Meeting adjourned by Sue Priola at 02:06 pm

Next Meeting

I. Scheduled October 16th 2025.

NIH RML Institutional Biosafety Committee Meeting

Biosafety Officer (BSO) Report

September 18, 2025

Business Conducted since the last IBC Meeting

A. BSO approvals
   a. None
B. Electronic business
   a. None

New business for IBC meeting

A. See agenda.

Division of Safety activities since the last IBC Meeting

A. Animal Study Protocols Review- Performed by Division of Safety staff
   a. 2 ASPs reviewed since the last IBC meeting.

B. Biosafety Training- Performed by Division of Safety staff

Type of Training	Number of Sessions	Number of Employees Trained
New Employee	n/a	n/a
Annual Refresher Lab Biosafety	n/a	n/a
Select Agent-Initial	1	4
Select Agent- Refresher	n/a	n/a
Select Agent- Visitor	n/a	n/a
BSL-3 Laboratory Biosafety-Initial	1	3
Practical Training	1	2
BSL-4 Laboratory Biosafety-Initial	n/a	n/a
Suit Training	n/a	n/a
Checklist Training	n/a	n/a
BSL-4 Laboratory Biosafety-Refresher & SA Refresher	1	53
Laboratory Biosafety Support Staff-Initial	n/a	n/a
Laboratory Biosafety Support Staff-Refresher	n/a	n/a
Laboratory Biosafety Support Staff-Refresher & SA Refresher	n/a	n/a
BSL-4 Medical Emergency Egress Training	n/a	n/a

C. Biological Incidents to Report
   a. None

D. Other Updates
   a. None